ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Marker Therapeutics Inc

Marker Therapeutics Inc (MRKR)

4.30
-0.035
(-0.81%)
Closed March 29 04:00PM
4.15
-0.15
(-3.49%)
After Hours: 07:59PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
4.30
Bid
4.03
Ask
4.82
Volume
19,804
4.15 Day's Range 4.55
0.6706 52 Week Range 9.6799
Market Cap
Previous Close
4.335
Open
4.33
Last Trade
30
@
4.47
Last Trade Time
Financial Volume
$ 86,179
VWAP
4.3516
Average Volume (3m)
20,122
Shares Outstanding
8,889,020
Dividend Yield
-
PE Ratio
-1.23
Earnings Per Share (EPS)
-3.37
Revenue
9.01M
Net Profit
-29.93M

About Marker Therapeutics Inc

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops prod... Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart. Show more

Sector
Pharmaceutical Preparations
Industry
Business Services, Nec
Headquarters
Wilmington, Delaware, USA
Founded
2006
Marker Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MRKR. The last closing price for Marker Therapeutics was $4.34. Over the last year, Marker Therapeutics shares have traded in a share price range of $ 0.6706 to $ 9.6799.

Marker Therapeutics currently has 8,889,020 shares outstanding. The market capitalization of Marker Therapeutics is $36.89 million. Marker Therapeutics has a price to earnings ratio (PE ratio) of -1.23.

MRKR Latest News

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant treated with MT-601 (Neldaleucel) following...

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies...

Form 8-K - Current report

false 0001094038 0001094038 2024-02-29 2024-02-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares  ...

Form 8-K - Current report

false 0001094038 0001094038 2024-02-22 2024-02-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares  ...

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

HOUSTON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies...

Form 8-K - Current report

false 0001094038 0001094038 2024-01-08 2024-01-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares  ...

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

Strategic prioritization of clinical programs with focus on MT-601 in patients with lymphoma MultiTAA-specific T cell therapies demonstrate clinical safety and positive clinical data across...

Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”

HOUSTON, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.22-4.867256637174.524.914.1101226684.5299423CS
40.6216.8478260873.684.913.4212534.22405807CS
12-0.99-18.71455576565.295.413.4201224.3528665CS
26-0.4-8.510638297874.76.15682.4522574.37334232CS
523.498436.1596009980.8029.67990.67062737192.5883613CS
156-19.1-81.623931623923.436.50.670661284311.39417053CS
260-63.2-93.629629629667.591.70.670666587420.18422983CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

MRKR Discussion

View Posts
learningcurve2020 learningcurve2020 16 hours ago
Boo!...You people have no sense of humor. Are you just gonna sit there like sad clowns or get up off your collective a-s and demand answers and management changes?
💩 1 🤡 1
learningcurve2020 learningcurve2020 1 day ago
MT-402?

>>Hope something comes out of MT-401
💩 1 🤡 1
microcapbiotech microcapbiotech 1 day ago
Thank You. Hope something comes out of MT-401 OTS.
👍️0
Buckboard Buckboard 2 days ago
Strange to say this to someone on a message board but I actually believe you. 8
👍️0
Phantom Lord Phantom Lord 2 days ago
Lol. Not ready for that yet but I promise I will make sure you hear the call.
👍️ 1
Buckboard Buckboard 2 days ago
Thanks. I was afraid you said Rose and I missed it.
👍️0
learningcurve2020 learningcurve2020 2 days ago
I'm having a difficult time understanding how anything like this T product can be effective and just crawl along like this. Feels like the usual Research for researches sake, and good salaries.
💩 1 🤡 1
Phantom Lord Phantom Lord 2 days ago
Nothing new which was to be expected. Just gave a recap of data we've already seen and reaffirmed the company's financial position. As of the latest release they are still on track to release lymphoma data within the next three months. Hopefully they don't release in Q2 earnings and try to pass it off as "1st half of the year" like they've done in the past.

The only real takeaways here are that Vera is still speaking highly of the lymphoma trial as we are nearing data and they have been in discussions with other pharma companies for a potential partnership. Vera's confidence has not seemed to waver and he is most certainly privy to all the data that we should be getting soon. I would have expected him to tone that down a bit if the data was looking shaky. Obviously, he could just be talking the trial up knowing that giving any hint of failure wouldn't look good but In my conversations with him in the past I don't get this vibe from him. Take that as you will. Like I've said in the past any partnership will require more data. Vera all but confirmed that in the presentation yesterday when asked about potential partnerships. Said they have talked to some other companies but they want to see more data to essentially "de-risk" any investment or partnership. Makes sense and is nothing we didn't already assume.

The lymphoma data that is coming soon seems to be the only thing we have to look forward to for a while. If data impresses the company should be able to have their path forward mapped out by the end of the year but I'm not expecting much else news this year other than that data and them initiating the MT-401 OTS trial which I don't expect to bring much interest until data starts to roll in most likely mid next year at the earliest. He mentioned the grant for the pancreatic trial as well but they don't have anything confirmed right now. If the pancreatic trial moves forward it will be with non-dilutive funding and will not effect the company's current cash runway. I will say, it is nice to see the company finally start taking their finances seriously.

All this being said if the lymphoma data is good it should warrant enough interest to at the very least keep the share price stable. We'll find out in roughly three months.
👍️0
learningcurve2020 learningcurve2020 3 days ago
Yeah, throw in TapImmune and this has been a very long and awful journey.
👍️ 1
ATLdoogie ATLdoogie 3 days ago
Dr. Juan.......Please speed things up. Another ten years and I'll be living in an urn.
👍️ 1
learningcurve2020 learningcurve2020 3 days ago
I suspect Vera's emphasis on "Non-dilutive financing" is his way of saying nobody will do business with us anymore after the nightmare performance.
👍️0
learningcurve2020 learningcurve2020 3 days ago
FISCAL YEAR 2023 FINANCIAL HIGHLIGHTS

Cash Position and Guidance: At December 31, 2023, Marker had cash and cash equivalents of $15.1 million. The Company believes that its existing cash and cash equivalents will fund its operating expenses into the fourth quarter of 2025, inclusive of available drawdowns from grant funds.

R&D Expenses: Research and development expenses were $10.4 million for the year ended December 31, 2023, compared to $12.0 million for the year ended December 31, 2022.

G&A Expenses: General and administrative expenses were $7.5 million for the year ended December 31, 2023, compared to $11.3 million for the year ended December 31, 2022.

Net Loss: Marker reported a net loss of $8.2 million for the year ended December 31, 2023, compared to a net loss of $29.9 million for the year ended December 31, 2022.

👍️0
microcapbiotech microcapbiotech 4 days ago
I'm guessing that this no new nothing news means that there ain't going to be any earth shattering news given by Juan at tomorrows presentation.
YAWN!
👍️0
microcapbiotech microcapbiotech 4 days ago
Ho Hum, it looks like the same Old information being told again for the 10th time.
Thanks for the update on lymphoma patient #1 again, again.
👍️0
microcapbiotech microcapbiotech 4 days ago
MARKER THERAPEUTICS REPORTS YEAR-END 2023 CORPORATE AND FINANCIAL RESULTS
https://ir.markertherapeutics.com/news-releases/news-release-details/marker-therapeutics-reports-year-end-2023-corporate-and
👍️0
microcapbiotech microcapbiotech 5 days ago
Hello Phantom, asking in advance. After Juan does his March 26 presentation, can you translate it here and give your outlook? Thank You
👍️ 1
microcapbiotech microcapbiotech 7 days ago
volume 17,000 , that's not a lot of excitment.
👍️0
jobynimble jobynimble 7 days ago
We are presenting at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on March 26, 2024!
Join our CEO Juan Vera and learn more about Marker’s #multiTAA T cell products.
📅 Date: March 26, 2024
⏰ Time: 10:00 AM, EDT
For more information: https://t.co/pS7hjNhblG pic.twitter.com/96sybCey1Y— Marker Therapeutics, Inc. (@MRKRTherapeutic) March 22, 2024
👍️0
microcapbiotech microcapbiotech 7 days ago
https://ir.markertherapeutics.com/news-releases/news-release-details/marker-therapeutics-present-hc-wainwright-2nd-annual-cell
👍️0
Buckboard Buckboard 7 days ago
Now 884 and thirteen cents up! I knew getting the name would do it.
👍️ 1
jobynimble jobynimble 7 days ago
I see volume of 30, lol…
👍️ 1
Buckboard Buckboard 7 days ago
Anyone know if this is halted for some fantastic news or just no interest? If the latter I'd like to thank the person who bought the 21 shares...
👍️ 1
microcapbiotech microcapbiotech 1 week ago
Nice move, but the pitiful volume Sucks.
👍️0
learningcurve2020 learningcurve2020 1 week ago
Maybe time to dress Phantom in short shorts with pom poms??
💩 1 🤡 1
microcapbiotech microcapbiotech 1 week ago
Ho Hum. go mrkr. rah rah rah.
👍️0
microcapbiotech microcapbiotech 2 weeks ago
Lymphoma patient #2? Lymphoma patient #3? We can expect some data when?
👍️0
learningcurve2020 learningcurve2020 3 weeks ago
Maybe the only thing harder than being a Mets fan is being a Marker shareholder.
💩 1 🤡 1
microcapbiotech microcapbiotech 3 weeks ago
Well, we can look at the bright side. At least we have the name "Neldaleucel" ready ... in case we ever get to use it to market ...
in 3 or 4 years if we're lucky.
GO METS you see we have out own "Acuna" now.
👍️0
bar1080 bar1080 3 weeks ago
"Likely you fell for yet another "Perpetual Startup" whose main purpose may be to continually pay huge salaries to insiders. Come back next month, next year, maybe twenty years from now and success will be just "around the corner."

What do you think insider salaries witll be like in 20 years?
💩 1 🤡 1
ATLdoogie ATLdoogie 3 weeks ago
Yes Sir, that about sums it up. My first buy was May 8 2012. I call it black Wednesday.
👍️ 1
learningcurve2020 learningcurve2020 3 weeks ago
Yep. Along with the reverse splits simply indescribable to non biotech investors.
👍️0
bar1080 bar1080 3 weeks ago
Likely you fell for yet another "Perpetual Startup" whose main purpose may be to continually pay huge salaries to insiders. Come back next month, next year, maybe twenty years from now and success will be just "around the corner."
💩 2 🤡 2
microcapbiotech microcapbiotech 3 weeks ago
OK, let me get this straight.
It has been more than 20 years since TPIV came public,
about 6 years since the MRKR merger,
and what we have to show for it is basically nothing.
All TPIV legacy gone bye bye.
MRKR AML just about gone bye bye.
And here we are, back to almost square one, with a single early Phase 1 Lymphoma trial.
Just Peachy.
👍️0
Buckboard Buckboard 3 weeks ago
Thanks
👍️0
jobynimble jobynimble 3 weeks ago
March 1st, the same day as the other news, I missed the 8-K alert so here it is…

https://www.sec.gov/ixviewer/ix.html?doc=/Archives/edgar/data/1094038/000110465924029638/tm247674d1_8k.htm

ITEM 1.02. TERMINATION OF A MATERIAL DEFINITIVE AGREEMENT

On February 29, 2024, Marker Therapeutics, Inc. (the “Company”) delivered notice to Lincoln Park Capital Fund, LLC, an Illinois limited liability company (“LPC”), terminating the Purchase Agreement, dated December 12, 2022 (the “Purchase Agreement”), with LPC effective March 1, 2024 (the “Termination Date”). The Company projects a financial runway through the fourth quarter of 2025 and does not anticipate an immediate need for capital acquisition. The Purchase Agreement provided that, upon the terms and subject to the conditions and limitations set forth therein, the Company had the right to sell to LPC up to $25 million of shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), over the 24-month term of the Purchase Agreement. The Purchase Agreement provided the Company could terminate the Purchase Agreement for any reason or for no reason with one business day notice to LPC, however, certain provisions in the Purchase Agreement survive termination, as more fully described in the Purchase Agreement. In consideration for entering into the Purchase Agreement, the Company issued to LPC 1,804,098 shares of the Company’s Common Stock (the “Commitment Shares”). There are no early termination penalties attributable the Purchase Agreement. There were no material relationships between the Company, or any of the Company’s affiliates, and LPC other than with respect to the Purchase Agreement and Registration Rights Agreement, described below.

Concurrently with entering into the Purchase Agreement, the Company also entered into a registration rights agreement with LPC (the “Registration Rights Agreement”), pursuant to which the Company agreed to file a Form S-1 registration statement (the “Registration Statement”), as permissible and necessary under the Securities Act of 1933, as amended (the “Securities Act”), to register the sale of the shares of the Company’s Common Stock that may be sold to LPC under the Purchase Agreement, as well as the Commitment Shares. On January 3, 2023, the Company filed a Prospectus Supplement to the Registration Statement dated December 23, 2022 and declared effective on December 30, 2022 with the Securities and Exchange Commission registering the resale of all the shares of Common Stock that may be offered to LPC from time to time under the Purchase Agreement. From December 12, 2022 through the Termination Date, the Company sold 12,500 shares of Common Stock under the Purchase Agreement generating proceeds of approximately $33,000. The Company has no further obligations under the Purchase Agreement.

The descriptions of the Purchase Agreement and the Registration Rights Agreement contained in this Current Report on Form 8-K do not purport to be complete and are qualified in their entirety by reference to the copies of the Purchase Agreement and the Registration Rights Agreement filed as Exhibit 10.1 and Exhibit 10.2, respectively, to the Current Report on Form 8-K filed on December 13, 2022.
👍️0
microcapbiotech microcapbiotech 3 weeks ago
Marker Therapeutics, Inc. has terminated its stock sale agreement with Lincoln Park Capital Fund, effective March 1, 2024, citing sufficient financial runway until the fourth quarter of 2025, negating the immediate need for further capital.
👍️0
learningcurve2020 learningcurve2020 4 weeks ago
Marker gives new meaning to "Curing one patient at a time".
💩 1 🤡 1
microcapbiotech microcapbiotech 4 weeks ago
Well, at least we were given information on the first lymphoma study participant for what, the FOURTH or FIFTH TIME now.
Thank You for the helpful update.
👍️0
microcapbiotech microcapbiotech 4 weeks ago
Do I detect a wee bit of sarcasm?
If so, I 100% agree with it.
👍️ 1
bar1080 bar1080 4 weeks ago
Compare feeble MRKR to the major stock indexes. Dow, S&P and QQQ are at or very near record highs. MRKR... not so much!. Even most small caps are doing pretty well lately..

💩 2 🤡 2
bar1080 bar1080 4 weeks ago
Of course MRKR is right back down and on almost no volume, while the broad stock market is doing super well. .
👍️0
Buckboard Buckboard 4 weeks ago
Thanks. I am much more optimistic about the company now!
👍️0
jobynimble jobynimble 4 weeks ago
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601
January 22, 2024 07:30 ET
| Source: Marker Therapeutics

HOUSTON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, announced today that the United States Adopted Names (USAN) Council, and the World Health Organization (WHO) International Nonproprietary Names (INN) expert committee has approved “neldaleucel” as the nonproprietary (generic) name for MT-601, a multi-tumor associated antigen (multiTAA)-specific T cell product candidate for the treatment of patients with lymphoma.

The USAN Council in close collaboration with the WHO established INN expert committee select and assign a single unique name of worldwide acceptability for each active substance that is to be marketed as a pharmaceutical, ensuring clear identification, safe prescription and dispensing of medicines to patients. Nonproprietary names are intended for use in pharmacopoeias, labelling, product information, advertising and other promotional material, drug regulation and scientific literature, and as a basis for product names, e.g. for generics. Their use is normally required by national and international legislations. The adoption of the name neldaleucel is a step forward for continued advancements of multiTAA therapies Marker is developing. The Company recently provided a clinical update on the Phase 1 study investigating MT-601 in CAR relapse patients with lymphoma, demonstrating clinical safety and durability in the first study participant, suggesting the clinical benefit of neldaleucel (Press Release, Dec 11, 2023).

“The assignment of the nonproprietary name to MT-601 represents a significant milestone as we advance this potential treatment for patients with lymphoma,” said Juan Vera, M.D., President and CEO of Marker Therapeutics. “The INN and USAN naming process meticulously evaluates proposed drug names for adherence to nomenclature guidelines and potential conflicts, followed by expert consensus and public review. The USAN and WHO INN approval of neldaleucel allows us to establish a universally recognized and conflict-free nonproprietary drug name for MT-601 and represents an important step in our path to ultimately market the drug.”
👍️0
jobynimble jobynimble 4 weeks ago
https://www.globenewswire.com/en/news-release/2024/01/22/2812937/0/en/Marker-Therapeutics-Receives-Approval-from-United-States-Adopted-Name-USAN-Council-and-International-Nonproprietary-Names-INN-Expert-Committee-for-Neldaleucel-as-Nonproprietary-Nam.html
👍️0
microcapbiotech microcapbiotech 1 month ago
Thank You, I guess that news is better than a sharp stick in the eye.
Now just let it lead to something meaningful and profitable.
👍️0
learningcurve2020 learningcurve2020 1 month ago
Well, it looks like Mr. Wilson connected with the right company anyway.
👍️0
InvestorCpt InvestorCpt 1 month ago
Doesn't seem like Monday premarket PR material.... that they are spending money with no meaningful communicated progress
👍️0
jobynimble jobynimble 1 month ago
You’re welcome…
👍️0
Buckboard Buckboard 1 month ago
Thanks
👍️0
jobynimble jobynimble 1 month ago
8-K filing: https://www.sec.gov/ixviewer/ix.html?doc=/Archives/edgar/data/1094038/000110465924027293/tm247177d1_8k.htm

ITEM 1.01. ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

On February 22, 2024, Marker Therapeutics, Inc. (the “Company”) entered into a Master Services Agreement for Product Supply (the “Agreement”) with Cell Ready LLC (“Cell Ready”). Cell Ready, which is owned by one of the Company’s directors and shareholders, Mr. John Wilson, is a contract development and manufacturing organization (CDMO).

Pursuant to the Agreement, the Company may contract with Cell Ready for the provision of various products and services from time to time by entering into work orders with Cell Ready. If the services involve the supply of product, Cell Ready is required to supply such product in conformance with the product requirements set forth in the applicable work order(s). The Agreement contains customary representations, warranties and indemnification provision. The initial term of the Agreement is three years and may be extended upon the mutual written agreement of the parties. Either party may terminate the Agreement (a) for material breach by the other party if such breach has not been cured within 30 days following notice of termination or (b) if the other party is the subject of an insolvency event.

Also on February 22, 2024, the Company entered into Work Order #1 under the Agreement, pursuant to which Cell Ready will provide the Company with GMP drug product for Marker MT-401 and/or MT-601. The services include the delivery of final drug product and quality control testing. The Company also requested Cell Ready to provide general support services in connection therewith. The total projected sum (inclusive of taxes) for the services under Work Order #1 are not anticipated to exceed $750,000. The services will cover the anticipated manufacturing costs for the first quarter of 2024. Additional Work Orders are expected to be generated for the remainder of 2024.
👍️0

Your Recent History

Delayed Upgrade Clock